RT Journal Article
T1 New Approaches in Nanomedicine for Ischemic Stroke
A1 Correa Paz, Clara
A1 Silva Candal, Andrés da
A1 Polo Tobajas, Ester
A1 Parcq, Jerome
A1 Vivien, Denis
A1 Maysinger, Dusica
A1 Pelaz García, Beatriz
A1 Campos Pérez, Francisco
K1 Cell tracking
K1 Diagnosis
K1 Drug carriers
K1 Drug control release
K1 Nanomedicine
K1 Neuroprotection
K1 Recovery
K1 Stroke
K1 Tissue plasminogen activator
AB Ischemic stroke, caused by the interruption of blood flow to the brain and subsequent neuronal death, represents one of the main causes of disability in developed countries. Therapeutic methods such as recanalization approaches, neuroprotective drugs, or recovery strategies have been widely developed to improve the patient’s outcome; however, important limitations such as a narrow therapeutic window, the ability to reach brain targets, or drug side effects constitute some of the main aspects that limit the clinical applicability of the current treatments. Nanotechnology has emerged as a promising tool to overcome many of these drug limitations and improve the efficacy of treatments for neurological diseases such as stroke. The use of nanoparticles as a contrast agent or as drug carriers to a specific target are some of the most common approaches developed in nanomedicine for stroke. Throughout this review, we have summarized our experience of using nanotechnology tools for the study of stroke and the search for novel therapies
PB MDPI
YR 2021
FD 2021
LK http://hdl.handle.net/10347/26254
UL http://hdl.handle.net/10347/26254
LA eng
NO Pharmaceutics 2021, 13(5), 757; https://doi.org/10.3390/pharmaceutics13050757
NO This project was supported by the FRQS, ISCIII (AC19/00031 and AC20/00041), and ANR under the framework of EuroNanoMed III_2020 (PLATMED_project); the European Union program FEDER and the European Regional Development Fund–ERDF; and the Xunta de Galicia (IN607D2020/03 and ED431G2019/03). E.P. and B.P acknowledge the AEI grants (PID2019-111218RB-I00 and RyC-2017-23457). Finally, F.C. thanks the ISCIII and Miguel Servet program (CPII19/00020)
DS Minerva
RD 27 abr 2026